Molecular Determination of Point Mutation Haplotypes in the Dihydrofolate Reductase and Dihydropteroate Synthase of Plasmodium falciparum in Three Districts of Northern Tanzania
Open Access
- 1 April 2003
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (4) , 1347-1354
- https://doi.org/10.1128/aac.47.4.1347-1354.2003
Abstract
The antimalarial combination of sulfadoxine and pyrimethamine (SP) was introduced as first-line treatment for uncomplicated malaria in Tanzania during 2001 following 18 years of second-line use. The genetic determinants of in vitro resistance to the two drugs individually are shown to be point mutations at seven sites in the dihydrofolate reductase gene ( dhfr ) conferring resistance to pyrimethamine and five sites in the dihydropteroate synthase ( dhps ) gene conferring resistance to sulfadoxine. Different combinations of mutations within each gene confer differing degrees of insensitivity, but information about the frequency with which allelic haplotypes occur has been lacking because of the complicating effects of multiple infection. Here we used a novel high-throughput sequence-specific oligonucleotide probe-based approach to examine the present resistance status of three Plasmodium falciparum populations in northern Tanzania. By using surveys of asymptomatic infections and screening for the presence of all known point mutations in dhfr and dhps genes, we showed that just five dhfr and three dhps allelic haplotypes are present. High frequencies of both triple-mutant dhfr and double-mutant dhps mutant alleles were found in addition to significant interregional heterogeneity in allele frequency. In vivo studies have shown that the cooccurrence of three dhfr mutations and two dhps mutations in an infection prior to treatment is statistically predictive of treatment failure. We have combined data for both loci to determine the frequency of two-locus genotypes. The triple- dhfr /double- dhps genotype is present in all three regions with frequencies ranging between 30 and 63%, indicating that treatment failure rates are likely to be high.Keywords
This publication has 47 references indexed in Scilit:
- Molecular Markers for Failure of Sulfadoxine‐Pyrimethamine and Chlorproguanil‐Dapsone Treatment ofPlasmodium falciparumMalariaThe Journal of Infectious Diseases, 2002
- Pyrimethamine–sulfadoxine resistance in Plasmodium falciparum: what next?Trends in Parasitology, 2001
- Rapid Selection ofPlasmodium falciparumDihydrofolate Reductase Mutants by Pyrimethamine ProphylaxisThe Journal of Infectious Diseases, 2000
- Sequence Variations in the Genes Encoding Dihydropteroate Synthase and Dihydrofolate Reductase and Clinical Response to Sulfadoxine‐Pyrimethamine in Patients with Acute Uncomplicated Falciparum MalariaThe Journal of Infectious Diseases, 2000
- Molecular Evidence of Greater Selective Pressure for Drug Resistance Exerted by the Long‐Acting Antifolate Pyrimethamine/Sulfadoxine Compared with the Shorter‐Acting Chlorproguanil/Dapsone on KenyanPlasmodium falciparumThe Journal of Infectious Diseases, 2000
- Malaria and anaemia at different altitudes in the Muheza district of Tanzania: childhood morbidity in relation to level of exposure to infectionPathogens and Global Health, 1998
- Polymorphisms in the dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) genes of Plasmodium falciparum and in vivo resistance to sulphadoxine/pyrimethamine in isolates from TanzaniaTropical Medicine & International Health, 1998
- Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilizationMolecular Microbiology, 1997
- Sequence Variation of the Hydroxymethyldihydropterin Pyrophosphokinase: Dihydropteroate Synthase Gene in Lines of the Human Malaria Parasite, Plasmodium falciparum, with Differing Resistance to SulfadoxineEuropean Journal of Biochemistry, 1994
- The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasitesPharmacology & Therapeutics, 1990